We are live on ! Find out more
CC

Checkpoint Capital Portfolio holdings

AUM $279M
1-Year Est. Return 45.74%
This Fund
S&P 500
This Quarter Est. Return
+3.78%
1 Year Est. Return
+45.74%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$215M
AUM Growth
+$32.3M
Cap. Flow
+$20.8M
Cap. Flow %
9.69%
Top 10 Hldgs %
100%
Holding
14
New
–
Increased
4
Reduced
4
Closed
6

Top Buys

Rank Stock Value
1
CORT icon
Corcept Therapeutics
CORT
+$24.6M
2
ARGX icon
argenx
ARGX
+$20.3M
3
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$9.35M
4
IRON icon
Disc Medicine
IRON
+$1.02M

Top Sells

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$12.4M
2
STOK icon
Stoke Therapeutics
STOK
+$4.86M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$4.51M
4
RVMD icon
Revolution Medicines
RVMD
+$4.3M
5
TCRX icon
TScan Therapeutics
TCRX
+$2.78M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARGX icon
1
argenx
ARGX
$54.1B
$82.7M 38.52%
149,977
+34,977
+30% +$20.3M
RYTM icon
2
Rhythm Pharmaceuticals
RYTM
$7.96B
$67M 31.21%
1,060,000
+152,760
+17% +$9.35M
CORT icon
3
Corcept Therapeutics
CORT
$12B
$25.2M 11.76%
343,917
+338,917
+6,778% +$24.6M
IRON icon
4
Disc Medicine
IRON
$2.97B
$14M 6.54%
265,000
+21,689
+9% +$1.02M
RVMD icon
5
Revolution Medicines
RVMD
$44B
$10.3M 4.8%
280,000
-112,011
-29% -$4.3M
SEPN
6
Septerna Inc
SEPN
$1.75B
$6.2M 2.89%
586,473
-238,405
-29% -$1.96M
KYMR icon
7
Kymera Therapeutics
KYMR
$8.94B
$4.67M 2.18%
106,991
-29,614
-22% -$1.02M
PTGX icon
8
Protagonist Therapeutics
PTGX
$9.44B
$4.49M 2.09%
81,311
-93,873
-54% -$4.51M
CDTX
9
DELISTED
Cidara Therapeutics
CDTX
– –
-104,380
Closed -$2.25M
IMCR icon
10
Immunocore
IMCR
$1.73B
– –
-9,011
Closed -$267K
RAPT
11
DELISTED
RAPT Therapeutics
RAPT
– –
-13,729
Closed -$134K
SLNO
12
DELISTED
Soleno Therapeutics
SLNO
– –
-172,902
Closed -$12.4M
STOK icon
13
Stoke Therapeutics
STOK
$2.11B
– –
-730,717
Closed -$4.86M
TCRX icon
14
TScan Therapeutics
TCRX
$52M
– –
-2,017,650
Closed -$2.78M

Similar funds

CB
Centennial Bank Conway, Arkansas $279M AUM 20.11% 1-Year Est. Return
SL
SOF Ltd George Town, Cayman Islands $279M AUM 6.12% 1-Year Est. Return
ACP
Arcus Capital Partners Atlanta, Georgia $278M AUM 14.53% 1-Year Est. Return
CCC
Compass Capital Corp Braintree, Massachusetts $279M AUM 28.36% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
NCM
NCM Capital Management Ramsey, New Jersey $279M AUM 26.47% 1-Year Est. Return
BWG
Balanced Wealth Group Westlake, Ohio $279M AUM 17.49% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

Checkpoint Capital's Q2 2025 Portfolio in Review

As of Q2 2025, Checkpoint Capital held 14 positions worth $215M, up 18% from $182M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Checkpoint Capital deployed $20.8M of net new capital in Q2 2025, adding to 4 existing holdings.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Protagonist Therapeutics, an estimated $4.51M trimmed.

  • Checkpoint Capital added most to Corcept Therapeutics in Q2 2025, an estimated $24.6M increase.
  • Checkpoint Capital's biggest Q2 2025 reduction was Protagonist Therapeutics, cutting an estimated $4.51M.
  • Checkpoint Capital fully exited Soleno Therapeutics in Q2 2025, selling an estimated $12.4M.
  • Checkpoint Capital's ten largest holdings make up 100% of its $215M portfolio in Q2 2025.
  • Checkpoint Capital opened 0 new positions and closed 6 in Q2 2025.
  • Checkpoint Capital's portfolio value rose 18% quarter-over-quarter to $215M.

Based on Checkpoint Capital's 13F filing for Q2 2025, filed 14 Aug 2025.